Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A patient who is the first in the UK to receive the world’s most advanced 'bionic eye' has been able to read the time for the first time in more than five years.

Mr James Ramsden, Mr Tom Edwards, Professor Robert MacLaren and Mr Matt Simunovic
Mr James Ramsden, Mr Tom Edwards, Professor Robert MacLaren and Mr Matt Simunovic

The moment Rhian Lewis, 49, realised she had correctly told the time is captured on BBC’s 'Trust Me I’m A Doctor', to be broadcast on Wednesday 6 January 2016.

Surgeons at the Oxford Eye Hospital at Oxford’s John Radcliffe Hospital implanted a tiny light-sensitive electronic chip at the back of Rhian’s retina in her right eye as part of ongoing clinical trials led by Robert MacLaren, Consultant Vitreoretinal Surgeon and Professor of Ophthalmology in the Nuffield Department of Clinical Neurosciences.

The work was funded by the National Institute for Health Research (NIHR) Invention for Innovation (i4i) programme in partnership with Retina Implant AG, the NIHR Oxford Biomedical Research Centre, and the NIHR Clinical Research Network.

Mother-of-two Rhian, of Cardiff, was diagnosed with retinitis pigmentosa – a disorder that destroys the light sensitive cells called photoreceptors in the retina – when she was five. She is completely blind in her right eye and has virtually no vision in her left eye as a result of the condition, for which there is no cure. But behind the destroyed photoreceptors she still had an intact optic nerve and all the brain wiring needed for vision, making it possible to restore vision if only a way could be found to substitute the function of the photoreceptors.

The wafer-thin retinal implant chip is inserted into the back of the eye to replace damaged photoreceptors in a delicate six to eight hour operation. The chip captures the light entering the eye to stimulate the nerve cells of the inner retina to deliver signals to the brain through the optic nerve. The device is connected to a tiny computer that sits underneath the skin behind the ear. This is powered by a magnetic coil which is applied to the skin – from the outside this looks similar to a hearing aid. The device is switched on once everything has healed up after the surgery.

It takes time for users to learn to interpret the sight the implant provides as, for most of the trial patients, the parts of the brain responsible for interpreting vision have been dormant for a long time. When the device is first switched on they will often see flashes of light, but over a few weeks the brain converts those flashes into meaningful shapes and objects to build up an image. This image is black and white and grainy, rather like early television pictures, but for patients who have spent years without any sight at all this improvement can be life changing.

One test involved Rhian looking closely at a large cardboard clock to see if she could tell the time correctly. She has not been able to tell the time with her right eye in 16 years and for about six years with her left eye. She said: 'Honest to God, that felt like Christmas Day', when she felt the clock to reveal she’d seen 3’o’clock correctly.

The 'bionic eye' as a treatment for retinitis pigmentosa has been tested in Oxford since 2012 and during this time the hospital has worked in close partnership with Retina Implant AG to develop the technology with the hope that it will one day be ready for use across the NHS. A total of six patients will be taking part in the latest trial at the John Radcliffe Hospital.

This ground-breaking research to create the world’s most advanced bionic eye highlights the crucial role of the NHS as a test bed for 21st century medicine. In investing over £1 billion a year into the National Institute for Health Research, we are helping to translate scientific advances into real benefits for patients.
- Minister for Life Sciences, George Freeman MP

Professor Robert MacLaren said: 'Restoring sight to the blind using an electronic device presents huge challenges for the technology, the surgery and above all, the patient. But at the same time, we know the huge potential benefit if we can get it right. I am delighted that the trial has started so successfully with the excellent results we have had so far with Rhian.'

Read more on the University of Oxford website...

Any trainee surgeons interested in pursuing a career in academic surgery in Oxford should look at the clinical ophthalmology vacancies page for more information.

Similar stories

Nine new Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Evaluating risk to people with epilepsy during the COVID-19 pandemic - study wins international prize

In May 2020 our researchers initiated a global project to investigate how COVID-19 has affected people with epilepsy, their carers and health care workers.

New European initiative to accelerate the discovery and validation of biomarkers for neurodegenerative diseases

Members of the European Platform for Neurodegenerative Diseases (EPND) will establish a collaborative platform for efficient sample and data sharing, linking existing European research infrastructures to accelerate the discovery of biomarkers, new diagnostics and treatments for the benefit of people with neurodegenerative diseases such as Alzheimer's and Parkinson's.

Major research network to investigate body clock and stroke

The University of Oxford is part of a new international research network to investigate the interactions between the biology of the body's internal clock and the disordered physiological processes associated with stroke.

COVID-19 infection has greater risk than vaccines of causing very rare neurological events

Research reveals risks of developing neurological complications following a positive COVID-19 PCR test, or a first dose of either the Oxford-AstraZeneca or Pfizer-BioNTech COVID-19 vaccinations.